Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/377
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorMOLENBERGHS, Geert-
dc.contributor.authorBURZYKOWSKI, Tomasz-
dc.contributor.authorRENARD, Didier-
dc.contributor.authorGEYS, Helena-
dc.date.accessioned2004-10-25T12:03:19Z-
dc.date.available2004-10-25T12:03:19Z-
dc.date.issued2000-
dc.identifier.citationDrug Information Journal, 34(2). p. 447-454-
dc.identifier.issn0092-8615-
dc.identifier.urihttp://hdl.handle.net/1942/377-
dc.description.abstractPrentice proposed a definition of surrogate endpoints and operational criteria for their validation. Freedman supplemented these criteria with the proportion explained, which is supposed to represent the proportion of the treatment effect upon the true endpoint which is mediated by the surrogate endpoint. In this paper, we argue that the proportion explained should be replaced by other quantities, such as the relative effect linking the effects of treatment on both endpoints and an individual-level measure of agreement between both endpoints. The latter quantity carries over naturally when data are available on several randomized experiments, while the former can be extended to be a trial-level measure of agreement between the effects of treatment of both endpoints. This approach suggests a new definition of surrogacy, and allows one to predict the effect of treatment upon the true endpoint, given its observed effect upon the surrogate endpoint.-
dc.language.isoen-
dc.publisherDRUG INFORMATION ASSOCIATION-
dc.rightsCopyright (C) 2000 Drug Information Association Inc.-
dc.subjectClinical trials-
dc.subjectClustered data-
dc.subjectSurrogate Markers-
dc.subject.othermeta-analysis; surrogate endpoint; validation-
dc.titleStatistical validation of surrogate endpoints: problems and proposals-
dc.typeJournal Contribution-
dc.identifier.epage454-
dc.identifier.issue2-
dc.identifier.spage447-
dc.identifier.volume34-
local.bibliographicCitation.jcatA1-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.bibliographicCitation.oldjcatA1-
dc.identifier.isi000087220200013-
dc.identifier.urlhttps://www.researchgate.net/profile/Marc_Buyse/publication/241646459_Statistical_Validation_of_Surrogate_Endpoints_Problems_and_Proposals/links/0c96052d22f6dd1de5000000/Statistical-Validation-of-Surrogate-Endpoints-Problems-and-Proposals.pdf-
item.fulltextWith Fulltext-
item.contributorBUYSE, Marc-
item.contributorMOLENBERGHS, Geert-
item.contributorBURZYKOWSKI, Tomasz-
item.contributorRENARD, Didier-
item.contributorGEYS, Helena-
item.fullcitationBUYSE, Marc; MOLENBERGHS, Geert; BURZYKOWSKI, Tomasz; RENARD, Didier & GEYS, Helena (2000) Statistical validation of surrogate endpoints: problems and proposals. In: Drug Information Journal, 34(2). p. 447-454.-
item.accessRightsRestricted Access-
item.validationecoom 2001-
crisitem.journal.issn0092-8615-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Statistical_Validation_of_Surrogate_Endpoints_Prob.pdf
  Restricted Access
Published version142.9 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.